ISM3312

ISM3312 is a small-molecule inhibitor of Methionine Adenosyltransferase 2A (MAT2A) developed by Insilico Medicine using its proprietary AI platform, Chemistry42. It is specifically designed to target cancers characterized by the deletion of the Methylthioadenosine Phosphorylase (MTAP) gene, a genomic alteration present in approximately 15% of all human tumors. In MTAP-deficient cells, the metabolite methylthioadenosine (MTA) accumulates and partially inhibits Protein Arginine Methyltransferase 5 (PRMT5). ISM3312 further reduces S-adenosylmethionine (SAM) levels, creating a synthetic lethal effect that selectively targets MTAP-deleted cancer cells while sparing normal tissues. The compound is currently in the IND-enabling stage of development.